Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19)

BACKGROUND: Cytokine release syndrome is a serious complication of the new coronavirus infection (COVID-19). The aim of the study was to assess effectiveness and safety of the IL-17 antagonist nekatimab for its treatment. METHODS: The retrospective study included COVID-19 patients with C-reactive pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Maslennikov, Roman, Ivashkin, Vladimir, Vasilieva, Ekaterina, Chipurik, Maxim, Semikova, Polina, Semenets, Victoria, Russkova, Tatyana, Levshina, Anna, Grigoriadis, Diana, Magomedov, Shamil, Efremova, Irina, Dzhakhaya, Natiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Libbey Eurotext 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491178/
https://www.ncbi.nlm.nih.gov/pubmed/34346869
http://dx.doi.org/10.1684/ecn.2021.0463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491178/
https://www.ncbi.nlm.nih.gov/pubmed/34346869
http://dx.doi.org/10.1684/ecn.2021.0463

Ejemplares similares